NCT04643405View on ClinicalTrials.gov

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

APG-1387 for Injection

APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.

DRUG

Nab paclitaxel

Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY